EN DE
Watch NewMed Energy - Limited Partnership for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

NewMed Energy - Limited Partnership (NWMD) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of NewMed Energy - Limited Partnership stock ILS 19.64, price ILS 16.95, upside +15.8%, quality 60 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Energy Il · ISIN IL0004750209

NE NewMed Energy - Limited Partnership logo Broad data Nov 18, 2026

NewMed Energy - Limited Partnership

NWMD · TA

Solid company, but only slightly cheap (14% below fair value) and price moving sideways: meets 1 of 3 rules.

Follow free in the weekly email
Fair value 19.64 ILS · Undervalued 
Quality 60/100 
Highly profitable · 31.1% net margin (TTM) 
Generates free cash flow 
Recent news very positive 
Broad data 
Last quarter vs. a year ago: revenue +53%, profit +45%. 
Price moving sideways (no uptrend) 
Moderate debt 
Mixed vs. peers (8/14) 
Wide moat 76/100 · thin data
Weak Growth (revenue 3y −6.4 %/yr in USD) 
⟳ CyclicalQuality growth

Main risks:

🚩Dependence on few export customers🚩Arbitration over terminated supply deal
Watch NewMed Energy - Limited Partnership for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

21.76 ILS 3.25 ILS Fair Value 19.64 ILS Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.

How to read this chart

60‑month range 3.25 ILS – 21.76 ILS · fair‑value band 9.28 ILS – 33.56 ILS · the 16.95 ILS price screens below the 19.64 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.

Follow NewMed Energy - Limited Partnership in your weekly email

Every Wednesday you see whether NewMed Energy - Limited Partnership is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NewMed Energy - Limited Partnership exploration, development, production, and marketing of natural gas, condensate, and oil in Israel, Jordan and Egypt.

Show moreShow less

The company holds interests in the Leviathan project, which covers an area of 500 square kilometer (km2) located to the west of the shores of Haifa; the Block 12 that covers an area of approximately 386 km2 located in Cyprus; and the Yam Tethys project, located to the west of the shores of Ashkelon.

It also holds interests in the Boujdour Atlantique exploration license that covers an area of approximately 33,815 km2 located in the south of the Moroccan exclusive economic zone; and the Tanin and Karish leases covering an area of approximately 500km2 located to the west of the shores of Nahariya.

The company serves independent power producers, marketing companies, and industrial customers, as well as exports natural gas to Jordan and in Egypt. The company was formerly known as Delek Drilling - Limited Partnership and changed its name to NewMed Energy - Limited Partnership in February 2022.

NewMed Energy - Limited Partnership was incorporated in 1993 and is based in Herzliya, Israel.

Stock analysis

NewMed Energy - Limited Partnership (NWMD) currently trades at 16.95 ILS, while our model-based Fair Value estimate is 19.64 ILS, implying the stock looks roughly 14% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 21.73 ILS per share, and 9 of the 26 models we run sit above the 16.95 ILS price.

Bear case: the Asset-Based group reads lowest at 3.53 ILS, and 17 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: 9.28 ILS (bear) to 33.56 ILS (bull), the price of 16.95 ILS sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Energy sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

NewMed Energy - Limited Partnership reported revenue of $938M in FY2025 versus $883M in FY2021, a compound +1.5%/yr. Reported net income was $371M in FY2025, compounding −2.1%/yr from FY2021.

Key figures

Market cap 19.9B ILS Mid · P/E ratio 23.5 · P/S ratio 9.32 · EPS (TTM) 0.7200 ILS · Dividend yield 4.1% · Net margin 39.6% · Return on equity 14.5% · Return on assets (EBIT) 15.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 76 out of 100 (low confidence).

What moves the price

The share trades about 22% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Energy peers we cover trades at 10% fair-value upside, at 16%, NWMD screens cheaper than that median.

Fair Value models

Bear 9.28 ILS Fair Value 19.64 ILS Bull 33.56 ILS
Price 16.95 ILS · Upside +15.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (0.0169 ILS per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 6.08 ILS 7.51 ILS 10.87 ILS 75
FCF DCF 10.07 ILS 19.82 ILS 43.73 ILS 74
EPV 6.83 ILS 8.38 ILS 9.69 ILS 74
All 26 models by family
DCF Models
FCF DCF 10.07 ILS 19.82 ILS 43.73 ILS 74
Owner Earnings 11.49 ILS 26.51 ILS 53.95 ILS 71
5Y Revenue Exit 2.33 ILS 5.34 ILS 9.25 ILS 69
5Y EBITDA Exit 6.96 ILS 15.76 ILS 27.56 ILS 72
5Y P/E Exit 7.81 ILS 17.77 ILS 29.94 ILS 68
10Y Revenue Exit 4.77 ILS 8.83 ILS 14.36 ILS 65
10Y EBITDA Exit 7.88 ILS 16.53 ILS 30.84 ILS 65
10Y P/E Exit 8.44 ILS 17.95 ILS 32.92 ILS 60
Earnings-Based
Graham-Dodd 7.03 ILS 43.54 ILS 60.78 ILS 63
Lynch FV 14.96 ILS 21.38 ILS 27.79 ILS 61
PEG = 1.0 14.96 ILS 21.38 ILS 27.79 ILS 57
EPV 6.83 ILS 8.38 ILS 9.69 ILS 74
Dividend Discount
Gordon GGM 6.04 ILS 11.49 ILS 16.61 ILS 67
DDM Multi-Stage 6.04 ILS 10.19 ILS 12.19 ILS 67
Multiples
P/E Multiple 10.86 ILS 14.48 ILS 18.10 ILS 63
P/S Multiple 2.35 ILS 3.14 ILS 3.92 ILS 58
P/B Multiple 7.11 ILS 9.48 ILS 11.84 ILS 55
EV/EBIT 9.01 ILS 12.95 ILS 16.89 ILS 65
EV/EBITDA 6.72 ILS 9.90 ILS 13.08 ILS 66
EV/Revenue n/a 0.3200 ILS 1.26 ILS 50
Asset-Based
NCAV (Graham) 2.63 ILS 3.53 ILS 5.26 ILS 54
Growth DCF
Growth DCF 9.57 ILS 21.72 ILS 40.15 ILS 74
Rev-Margin DCF 2.33 ILS 5.44 ILS 9.82 ILS 69
Economic Profit
Residual Income 6.08 ILS 7.51 ILS 10.87 ILS 75
ROIC Compounder 7.82 ILS 12.28 ILS 16.14 ILS 71
Growth Earnings
Growth-Adj P/E 15.21 ILS 21.73 ILS 28.25 ILS 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 75
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 44
Does it invest with discipline instead of growing at any price?
Low Volatility 78
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 30
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−17.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +14.3% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.3%
Dividend (yield on the price)4.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.3% vs 8.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.52% → 60%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.3% a year for the price.

Watch NWMD, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (34 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare NewMed Energy - Limited Partnership with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Oil & Gas E&P · 283 stocks

Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 60 · Top 25%
Fair Value upside +15.8% · Top 25%
Profitability
Return on equity (12 months) 14.5% · Top 25%
Return on assets 9.4% · Top 25%
Net margin (12 months) 31.1% · Top 25%
Operating margin (12 months) 48.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 52.5% · Top 25%
Dividend yield (12 months) 4.1% · Above median
Balance sheet
Debt / equity 0.74× · Highest 25%

Valuation Multiplesvs Oil & Gas E&P median · lower = cheaper

P/E (12 months) 23.5× · Priciest 25%
P/B 3.20× · Priciest 25%
P/S (12 months) 7.14× · Priciest 25%
Price / free cash flow (fiscal year) 19.9× · Pricier than median
EV/EBITDA 11.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)54 · sector 25
FUTURE (revenue growth)100 · sector 100
PAST (return on equity)58 · sector 19
HEALTH (low debt)63 · sector 85
DIVIDEND (yield)83 · sector 72

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Oil & gas

Similar stocks

10 more Oil & Gas E&P stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Expand Energy Corporation EXE $84.47 $164.80 +95% vs NWMD
Diamondback Energy, Inc FANG $174.32 $242.64 +39% vs NWMD
CNOOC Limited 0883 HK$22.12 HK$26.82 +21% vs NWMD
Canadian Natural Resources Limited CNQ $45.53 $52.51 +15% vs NWMD
EQT Corporation EQT $50.69 $55.76 +10% vs NWMD
Woodside Energy Group WDS $20.08 $19.51 −3% vs NWMD
Devon Energy Corporation DVN $41.96 $39.23 −7% vs NWMD
ConocoPhillips explores for, COP $134.40 $92.89 −31% vs NWMD
Occidental Petroleum Corporation OXY $53.76 $33.18 −38% vs NWMD
Aker BP ASA AKRBP kr 318.40 kr 128.80 −60% vs NWMD

Explore undervalued stocks

More undervalued Energy stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NewMed Energy - Limited Partnership: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NewMed Energy - Limited Partnership Fair Value". https://www.fairvalue-calculator.com/stock/NWMD

Frequently asked questions

Is NewMed Energy - Limited Partnership (NWMD) overvalued or undervalued?
As of Nov 18, 2026, our model estimates a fair value of 19.64 ILS versus a price of 16.95 ILS, about +16% upside (undervalued).
What is the fair value of NWMD?
Our model-based fair value for NewMed Energy - Limited Partnership is 19.64 ILS (as of Nov 18, 2026), built from audited fundamentals. The current price: 16.95 ILS.
What is the quality score of NWMD?
NewMed Energy - Limited Partnership has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NewMed Energy - Limited Partnership (NWMD)?
We do not set a price target; the yardstick is the fair value of 19.64 ILS (as of Nov 18, 2026) from 26 valuation models. Cautious scenario 9.28 ILS, optimistic scenario 33.56 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the NewMed Energy - Limited Partnership stock forecast for 2026?
Our models put fair value at 19.64 ILS, about +16% upside versus a price of 16.95 ILS (undervalued). Cautious scenario 9.28 ILS, optimistic scenario 33.56 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of NewMed Energy - Limited Partnership (NWMD)?
NewMed Energy - Limited Partnership reported trailing-twelve-month revenue of about $848M (latest available figure, as of Nov 18, 2026).
Does NewMed Energy - Limited Partnership pay a dividend?
NewMed Energy - Limited Partnership currently shows a dividend yield of 4.14% relative to its recent price (as of Nov 18, 2026).
How much is the dividend of NewMed Energy - Limited Partnership (NWMD) and when is the ex-dividend date?
NewMed Energy - Limited Partnership pays a dividend of 0.701 ILS per share a year, a dividend yield of 4.1%. The last ex-dividend date was Aug 24, 2026. A dividend has been paid every year since 2014. The payout ratio is 67.5% of earnings. Free cash flow covers the dividend 1.22 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into NewMed Energy - Limited Partnership (NWMD)?
For today's price to be fair in a discounted-cash-flow model, NewMed Energy - Limited Partnership would have to grow free cash flow by 14.0 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 9.8 % per year. As of Nov 18, 2026.
What discount rate (WACC) does the fair value of NWMD use?
Our models discount NewMed Energy - Limited Partnership at 10.1 %: a base by market capitalisation (mid), damped by beta 0.46, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NewMed Energy - Limited Partnership that is +14.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has NewMed Energy - Limited Partnership (NWMD) delivered so far?
Over the past 5 years revenue at NewMed Energy - Limited Partnership grew 9.8 % a year. The price currently implies free-cash-flow growth of +14.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NewMed Energy - Limited Partnership (NWMD) growing?
The median revenue growth in the sector is +14.5 % a year. That is the yardstick for the growth priced into NewMed Energy - Limited Partnership (+14.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NewMed Energy - Limited Partnership (NWMD)?
The free-cash-flow yield on the price is 5.03 %: that much free cash flow NewMed Energy - Limited Partnership produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NewMed Energy - Limited Partnership (NWMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NewMed Energy - Limited Partnership it is 19.64 ILS per share (as of Nov 18, 2026), against a price of 16.95 ILS. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is NewMed Energy - Limited Partnership stock overvalued or undervalued in 2026?
As of Nov 18, 2026, NWMD trades below its calculated fair value: price 16.95 ILS, fair value 19.64 ILS, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NWMD?
No. The price is what the market pays today (16.95 ILS); the fair value is what the company's own numbers justify (19.64 ILS). For NewMed Energy - Limited Partnership the two are 2.69 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is NewMed Energy - Limited Partnership worth?
The market values NewMed Energy - Limited Partnership at about 19.9B ILS (market capitalisation, as of Nov 18, 2026). Per share that is 16.95 ILS; our models calculate a fair value of 19.64 ILS per share.
What do the bullish and bearish scenarios say about NWMD?
Our models span a range for NewMed Energy - Limited Partnership: cautious scenario 9.28 ILS, base 19.64 ILS, optimistic 33.56 ILS per share (as of Nov 18, 2026, price 16.95 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NWMD?
NewMed Energy - Limited Partnership trades at a price-to-earnings ratio of 23.5 (as of Nov 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 19.64 ILS is built from several models across several years. Other multiples: P/B 3.2, P/S 7.1, EV/EBITDA 11.0.
How solid is the balance sheet of NewMed Energy - Limited Partnership (NWMD)?
Balance-sheet figures for NewMed Energy - Limited Partnership (as of Nov 18, 2026): return on equity 14.5%, debt of 0.74 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is NWMD from its 52-week high?
NewMed Energy - Limited Partnership trades at 16.95 ILS, about 22% below its 52-week high of 21.76 ILS and 11% above the low of 15.31 ILS (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 19.64 ILS is for.
Which stocks are comparable to NewMed Energy - Limited Partnership?
From the same area (Energy) we also value ConocoPhillips explores for,, CNOOC Limited, Canadian Natural Resources Limited, Diamondback Energy, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NewMed Energy - Limited Partnership stock attractive at the current price?
The data as of Nov 18, 2026: price 16.95 ILS, calculated fair value 19.64 ILS (+16%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NWMD calculated?
We run NewMed Energy - Limited Partnership through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 19.64 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. NewMed Energy - Limited Partnership currently trades 14% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NewMed Energy - Limited Partnership (NWMD)?
The closing price on Nov 19, 2026 was 16.95 ILS. Our model-based fair value is 19.64 ILS, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NewMed Energy - Limited Partnership right now?
The model range is unusually wide (9.28 ILS to 33.56 ILS). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of NewMed Energy - Limited Partnership (NWMD) come from?
Earnings per share at NewMed Energy - Limited Partnership grew 10.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.1 %, EBIT margin +2.3 %, tax rate −2.9 %, residual (interest, one-offs) +0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of NewMed Energy - Limited Partnership

How large is the market capitalisation of NewMed Energy - Limited Partnership (NWMD)?
The market capitalisation of NewMed Energy - Limited Partnership is 19.9B ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NewMed Energy - Limited Partnership (NWMD)?
The price-to-sales ratio of NewMed Energy - Limited Partnership is 9.32 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NewMed Energy - Limited Partnership (NWMD)?
Earnings per share at NewMed Energy - Limited Partnership are 0.7200 ILS (price ÷ EPS = P/E 23.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NewMed Energy - Limited Partnership (NWMD)?
The dividend yield of NewMed Energy - Limited Partnership is 4.1% (payout 97.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NewMed Energy - Limited Partnership (NWMD)?
The net margin of NewMed Energy - Limited Partnership is 39.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NewMed Energy - Limited Partnership (NWMD)?
The return on equity (ROE) of NewMed Energy - Limited Partnership is 14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NewMed Energy - Limited Partnership (NWMD)?
On an EBIT basis the return on assets of NewMed Energy - Limited Partnership is 15.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NewMed Energy - Limited Partnership (NWMD)?
The operating margin of NewMed Energy - Limited Partnership is 48.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NewMed Energy - Limited Partnership (NWMD)?
Revenue at NewMed Energy - Limited Partnership is growing 52.5% versus a year earlier (3y avg −6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NewMed Energy - Limited Partnership (NWMD)?
Earnings per share at NewMed Energy - Limited Partnership are growing 45.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does NewMed Energy - Limited Partnership (NWMD) carry?
The net debt of NewMed Energy - Limited Partnership is $1.0B (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch NewMed Energy - Limited Partnership in the live analysis

One click puts NewMed Energy - Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.